Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version — setting out what I have, and where I think it stops being reliable.
A narrow question about Older adults, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no answer.
One question, stated units, stated method, and what I have already ruled out.
Older adults has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
A note on scope: what I am saying about Older adults applies to the case in the first post and I would not extend it further without checking.
Post #3 answers the question as asked. The question underneath it is different.
The most useful contribution here is usually a citation to whichever published document comes closest, with a plain statement of how far it is from the question.
Happy to expand any of that if it is the useful part.
Adding a null result on Older adults. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
Coming back to post #3, because the follow-up matters more than the original answer.
Hypoglycemia risk: in people already on insulin or sulfonylureas, adding a GLP-1 agonist requires insulin dose reduction and close monitoring for hypoglycemia. This is manageable with attention.
I would want a second opinion before relying on that.
Post #7 is right about the mechanism and I think understates the practical bit.
What I would tell a new member reading about Older adults for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Adding the measurement that post #7 says would settle it.
Distinguishing three things in the Older adults discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Post #8 answers the question as asked. The question underneath it is different.
Older adults were included in the trials in smaller numbers than their share of the eventual population, so precision in that subgroup is poor.
Speaking for myself and not for anyone else who has posted here.
I disagree with the framing of Older adults above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
Being outside the studied population does not mean a treatment is unsafe. It means the usual evidence is not available and the reasoning has to be explicit.
Coming back to post #14, because the follow-up matters more than the original answer.
Adolescents: a distinct evidence base exists. The compounds are not approved for routine adolescent obesity but are being studied. Adolescent physiology and psychology differ from adults' in ways that matter for this medication class.
A weak preference rather than a position.
Practical note on Older adults: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
Older adults is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
On Older adults, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Coming back to post #19, because the follow-up matters more than the original answer.
Older adults is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Nothing in this subcategory is medical advice and the questions asked here are precisely the ones that need an individual assessment.
Older adults: sarcopenia risk is higher, polypharmacy is common, and the clinical trials did not enroll many people over 75. Extrapolating to very old people is extrapolating beyond the data.
The part I am sure of is shorter than the part I have written.
This follows post #23 rather than contradicting it.
Genuine question rather than a rhetorical one: has anyone here actually observed Older adults, as opposed to read about it? The thread is long and I cannot tell.
I had written a reply contradicting post #23 and deleted it. Here is what survived.
Adolescents: a distinct evidence base exists. The compounds are not approved for routine adolescent obesity but are being studied. Adolescent physiology and psychology differ from adults' in ways that matter for this medication class.
The literature is thinner on this than the confidence in the thread implies.
Following this. I have the same question and no better information than the first post.
Dedicated trials in under-studied populations are the only real remedy and several are ongoing, which is worth saying rather than speculating.
Two people in this thread mean different things by Older adults and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.